Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Soffietti, 2010, Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force, Eur J Neurol, 17, 1124, 10.1111/j.1468-1331.2010.03151.x

Douw, 2009, Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up, Lancet Neurol, 8, 810, 10.1016/S1474-4422(09)70204-2

Pignatti, 2002, Prognostic factors for survival in adult patients with cerebral low-grade glioma, J Clin Oncol, 20, 2076, 10.1200/JCO.2002.08.121

Jenkins, 2006, A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma, Cancer Res, 66, 9852, 10.1158/0008-5472.CAN-06-1796

Suzuki, 2015, Mutational landscape and clonal architecture in grade II and III gliomas, Nat Genet, 47, 458, 10.1038/ng.3273

Karim, 1996, A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844, Int J Radiat Oncol Biol Phys, 36, 549, 10.1016/S0360-3016(96)00352-5

van den Bent, 2005, Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial, Lancet, 366, 985, 10.1016/S0140-6736(05)67070-5

Shaw, 2002, Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study, J Clin Oncol, 20, 2267, 10.1200/JCO.2002.09.126

Buckner, 2016, Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, N Engl J Med, 374, 1344, 10.1056/NEJMoa1500925

Stupp, 2001, Current and future developments in the use of temozolomide for the treatment of brain tumours, Lancet Oncol, 2, 552, 10.1016/S1470-2045(01)00489-2

Hoang-Xuan, 2004, Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions, J Clin Oncol, 22, 3133, 10.1200/JCO.2004.10.169

Quinn, 2003, Phase II trial of temozolomide in patients with progressive low-grade glioma, J Clin Oncol, 21, 646, 10.1200/JCO.2003.01.009

Brada, 2003, Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas, Ann Oncol, 14, 1715, 10.1093/annonc/mdg371

Ricard, 2007, Dynamic history of low-grade gliomas before and after temozolomide treatment, Ann Neurol, 61, 484, 10.1002/ana.21125

Tolcher, 2003, Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules, Br J Cancer, 88, 1004, 10.1038/sj.bjc.6600827

Brandes, 2006, Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO), Br J Cancer, 95, 1155, 10.1038/sj.bjc.6603376

Wick, 2007, Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma, J Clin Oncol, 25, 3357, 10.1200/JCO.2007.10.7722

Reijneveld, 2016, Health-related quality of life in patients with high-risk low-grade glioma: a randomised, controlled, phase 3 trial, Lancet Oncol, 10.1016/S1470-2045(16)30305-9

Kleihues, 2000

Yan, 2009, IDH1 and IDH2 mutations in gliomas, N Engl J Med, 360, 765, 10.1056/NEJMoa0808710

Weber, 2011, Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting, Radiother Oncol, 100, 150, 10.1016/j.radonc.2011.05.073

Musat, 2010, Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033–26033: first evaluation of quality of radiotherapy planning, Radiother Oncol, 95, 218, 10.1016/j.radonc.2010.03.005

Fairchild, 2012, Quality assurance in the EORTC 22033–26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review, Radiother Oncol, 103, 287, 10.1016/j.radonc.2012.04.002

Hartmann, 2005, Molecular genetic analysis of oligodendroglial tumors, J Neuropathol Exp Neurol, 64, 10, 10.1093/jnen/64.1.10

Seiz, 2010, Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes, Acta Neuropathol, 120, 261, 10.1007/s00401-010-0701-2

Reuss, 2015, ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma, Acta Neuropathol, 129, 133, 10.1007/s00401-014-1370-3

Bady, 2012, MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status, Acta Neuropathol, 124, 547, 10.1007/s00401-012-1016-2

Bady, 2016, Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors, J Mol Diagn, 18, 350, 10.1016/j.jmoldx.2015.11.009

Ceccarelli, 2016, Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma, Cell, 164, 550, 10.1016/j.cell.2015.12.028

Wiestler, 2014, Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma, Acta Neuropathol, 128, 561, 10.1007/s00401-014-1315-x

Weller, 2015, Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups, Acta Neuropathol, 129, 679, 10.1007/s00401-015-1409-0

2016

Reuss, 2015, Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities, Acta Neuropathol, 129, 407, 10.1007/s00401-015-1454-8

Reuss, 2015, IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO, Acta Neuropathol, 129, 867, 10.1007/s00401-015-1438-8

Turcan, 2012, IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype, Nature, 483, 479, 10.1038/nature10866

van den Bent, 2013, MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas. A report from EORTC study 26951, Clin Cancer Res, 19, 5513, 10.1158/1078-0432.CCR-13-1157

Wick, 2013, Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation, Neurology, 81, 1515, 10.1212/WNL.0b013e3182a95680

Boele, 2015, Health-related quality of life in stable, long-term survivors of low-grade glioma, J Clin Oncol, 33, 1023, 10.1200/JCO.2014.56.9079

Correa, 2007, Cognitive functions in low-grade gliomas: disease and treatment effects, J Neurooncol, 81, 175, 10.1007/s11060-006-9212-3

Wick, 2016, Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide, Neuro Oncol, 10.1093/neuonc/now133

van den Bent, 2013, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J Clin Oncol, 31, 344, 10.1200/JCO.2012.43.2229

Cairncross, 2013, Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J Clin Oncol, 31, 337, 10.1200/JCO.2012.43.2674

Pallud, 2012, Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas, Neuro Oncol, 14, 496, 10.1093/neuonc/nos069

Cairncross, 2014, Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH, J Clin Oncol, 32, 783, 10.1200/JCO.2013.49.3726